domingo, 20 de octubre de 2013

Effect of the 12-Gene Colon Cancer Assay R... [Curr Med Res Opin. 2013] - PubMed - NCBI

Effect of the 12-Gene Colon Cancer Assay R... [Curr Med Res Opin. 2013] - PubMed - NCBI


2013 Oct 16. [Epub ahead of print]


Effect of the 12-Gene Colon Cancer Assay Results on Adjuvant Treatment Recommendations in Patients with Stage II Colon Cancer.





Source


Ocala Oncology, Ocala, FL.



Abstract



Abstract Introduction: The 12-gene colon cancer Recurrence Score assay is a clinically validated predictor of recurrence risk in stage II colon cancer patients. We performed a survey characterizing the assay's impact on treatment recommendations for these patients. Methods: U.S. medical oncologists (N=346) who ordered the assay for ≥3 stage II colon cancer patients were asked to complete a web-based survey regarding their most recent such patient. Physicians surveyed represented users of the assay within the first two years of commercial availability which may include 'early adopters.' Results: Most of 116 eligible physicians were in community practice (86%), with median 14.5 years' experience (range, 2-40). Mean patient age was 61 years (range, 32-85); 81% had T3 disease and 38% had comorbidities. Of 76 patients tested for mismatch-repair/microsatellite-instability (MMR/MSI), 13 (17%) were MMR-deficient/MSI-high; 46 (61%) MMR-proficient/MSI-low; and 17 (22%) unknown. Most patients (84%) had ≥12 nodes examined. Median Recurrence Score result was 20 (range, 1-77). Before assay, treatment recommendations were specified for 92 (79%) patients, with no recommendation for 24 (21%). Of the 92 with pre-assay recommendations, chemotherapy was planned for 52 (57%) and observation for 40 (43%); the assay changed recommendations for 27 (29%). Treatment intensity decreased for 18 (67%) and increased for 9 (33%) patients; it was more likely to decrease for lower Recurrence Score values and increase for higher values (P<0 .001="" 29="" 2="" and="" assay="" availability="" cancer="" changed.="" colon="" conclusion:="" data="" design="" during="" first="" for="" gathering="" ii="" in="" include="" intensity.="" lead="" limitations="" may="" non-representativeness="" of="" only="" p="" patients="" potential="" receiving="" recommendations="" recurrence="" reductions="" respondents.="" retrospective="" score="" stage="" study="" testing="" the="" to="" treatment="" use="" were="" years="">






PMID:

24127781
[PubMed - as supplied by publisher]



No hay comentarios:

Publicar un comentario